HANSOH PHARMA's Novel Drug HS-10541 Tablets Receive Clinical Trial Approval from NMPA

Stock News05-13

HANSOH PHARMA (03692) has announced that its self-developed Class 1 novel drug, HS-10541 tablets, has received a drug clinical trial approval notice from the National Medical Products Administration (NMPA) of China. The clinical trial is intended to investigate the treatment of advanced solid tumors with KRAS G12C mutations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment